{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:59Z","timestamp":1792036859505,"version":"4.4.0"},"reference-count":115,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Multiple myeloma is the second-most common hematologic malignancy in adults worldwide. Despite ongoing advancement in therapeutic modalities, it remains an incurable disease with a 5-year survival rate of approximately 50%. The recent development and introduction of anti-BCMA immunotherapies into clinical practice, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies, has radically shifted the treatment paradigm. However, despite the promising potential of these therapies for broader application, frequent and significant adverse effects have been reported, both in short- and in long-term settings, requiring increasing awareness and vigilance in the treating team, close monitoring, and prompt interventions with a multidisciplinary approach. In this review, we will discuss the toxicities associated with CAR-T cell and bispecific antibody therapies, focusing on results from major clinical studies and real-world observations. In addition, we will emphasize on effective strategies for prevention, monitoring and management, and provide expert recommendations.<\/jats:p>","DOI":"10.3390\/curroncol30070467","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T01:03:02Z","timestamp":1688346182000},"page":"6330-6352","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-7337","authenticated-orcid":false,"given":"Mariam","family":"Markouli","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA 02118, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-1202","authenticated-orcid":false,"given":"Fauzia","family":"Ullah","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0425-5030","authenticated-orcid":false,"given":"Serhan","family":"Unlu","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najiullah","family":"Omar","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6207-2371","authenticated-orcid":false,"given":"Nerea","family":"Lopetegui-Lia","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Duco","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cleveland Clinic Foundation, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2265","authenticated-orcid":false,"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-7975","authenticated-orcid":false,"given":"Danai","family":"Dima","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA"},{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dima, D., Jiang, D., Singh, D.J., Hasipek, M., Shah, H.S., Ullah, F., Khouri, J., Maciejewski, J.P., and Jha, B.K. (2022). Multiple Myeloma Therapy: Emerging Trends and Challenges. Cancers, 14.","DOI":"10.3390\/cancers14174082"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dima, D., Ullah, F., Mazzoni, S., Williams, L., Faiman, B., Kurkowski, A., Chaulagain, C., Raza, S., Samaras, C., and Valent, J. (2023). Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice. Cancers, 15.","DOI":"10.3390\/cancers15072160"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific Antibodies in Multiple Myeloma Treatment: A Journey in Progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-Cell Therapy in Multiple Myeloma: More Room for Improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/jha2.338","article-title":"Overview of Approved CAR-T Therapies, Ongoing Clinical Trials, and Its Impact on Clinical Practice","volume":"3","author":"Sengsayadeth","year":"2022","journal-title":"EJHaem"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3389\/fonc.2020.00885","article-title":"Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective","volume":"10","author":"Sievers","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.3389\/fimmu.2020.620312","article-title":"Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.3389\/fimmu.2022.1050522","article-title":"Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global Manufacturing of CAR T Cell Therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"991092","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene Autoleucel: The Second Anti-BCMA CAR T-Cell Therapeutic Armamentarium of Relapsed or Refractory Multiple Myeloma","volume":"13","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-Cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T Cell-Engaging Therapies\u2014BiTEs and Beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/ajh.26628","article-title":"Bispecific T-Cell Engagers for Treatment of Multiple Myeloma","volume":"98","author":"Ravi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_15","first-page":"10036","article-title":"A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"40","author":"Elmeliegy","year":"2022","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy","volume":"22","author":"Morris","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41421-021-00299-6","article-title":"Chimeric Antigen Receptor T Cells Self-Neutralizing IL6 Storm in Patients with Hematologic Malignancy","volume":"7","author":"Xue","year":"2021","journal-title":"Cell Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine Release Syndrome: Current Perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Cosenza, M., Sacchi, S., and Pozzi, S. (2021). Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. Int J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147652"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious Complications in Patients with Relapsed Refractory Multiple Myeloma after BCMA CAR T-Cell Therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv."},{"key":"ref_22","first-page":"5209","article-title":"Hemophagocytic Lymphohistiocytosis\/Macrophage Activation Syndrome (HLH\/MAS) Following Treatment with Tisagenlecleucel","volume":"10","author":"Bastos","year":"2022","journal-title":"Clin. Case Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric Antigen Receptor T-Cell Therapy\u2014Assessment and Management of Toxicities","volume":"15","author":"Neelapu","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2083479","DOI":"10.1080\/2162402X.2022.2083479","article-title":"Novel Strategies for the Mitigation of Cytokine Release Syndrome Induced by T Cell Engaging Therapies with a Focus on the Use of Kinase Inhibitors","volume":"11","author":"Leclercq","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine Release Syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11684-019-0714-8","article-title":"Management of Cytokine Release Syndrome Related to CAR-T Cell Therapy","volume":"13","author":"Chen","year":"2019","journal-title":"Front. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood-2021-146518","article-title":"Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy Bb21217 in Patients with Relapsed and Refractory Multiple Myeloma","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene Autoleucel (Orva-Cel), a B-Cell Maturation Antigen (BCMA)-Directed CAR T Cell Therapy for Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Update of the Phase 1\/2 EVOLVE Study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.2021.39.15_suppl.2537","article-title":"Anakinra (AKR) Prophylaxis (Ppx) in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM) Receiving Orvacabtagene Autoleucel (Orva-Cel)","volume":"39","author":"Costa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-139802","article-title":"Results from Lummicar-2: A Phase 1b\/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial","volume":"41","author":"Xia","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-Shelf\u2019 Allogeneic CAR T Cells: Development and Challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-Targeting CAR T Cells in Relapsed\/Refractory Multiple Myeloma: Phase 1 UNIVERSAL Trial Interim Results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab Is an Active T Cell-Redirecting Bispecific Antibody against B-Cell Maturation Antigen for Multiple Myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma (MajesTEC-1): A Multicentre, Open-Label, Single-Arm, Phase 1 Study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-Cell-Redirecting Bispecific G-Protein-Coupled Receptor Class 5 Member D x CD3 Antibody to Treat Multiple Myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine Release Syndrome with Novel Therapeutics for Acute Lymphoblastic Leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (Axi-Cel; KTE-C19) Treatment for Patients with Refractory, Aggressive Non-Hodgkin Lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"De Philippis, C., Mannina, D., Giordano, L., Costantini, E., Marcheselli, S., Mariotti, J., Sarina, B., Taurino, D., Santoro, A., and Bramanti, S. (2023). Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma. Transpl. Cell Ther.","DOI":"10.1016\/j.jtct.2023.03.019"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e000621","DOI":"10.1136\/jitc-2020-000621","article-title":"Tocilizumab, but Not Dexamethasone, Prevents CRS without Affecting Antitumor Activity of Bispecific Antibodies","volume":"8","author":"Kauer","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of Adults and Children Undergoing Chimeric Antigen Receptor T-Cell Therapy: Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Chabannon","year":"2020","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2147\/JBM.S281247","article-title":"Assessing and Management of Neurotoxicity after CAR-T Therapy in Diffuse Large B-Cell Lymphoma","volume":"12","author":"Chavez","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/practneurol-2020-002550","article-title":"Neurotoxicity\u2014CAR T-Cell Therapy: What the Neurologist Needs to Know","volume":"20","author":"Neill","year":"2020","journal-title":"Pr. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of Neurotoxicity in a Series of Patients Treated with CAR T-Cell Therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mcn.2014.01.002","article-title":"Selective Regulation of Axonal Growth from Developing Hippocampal Neurons by Tumor Necrosis Factor Superfamily Member APRIL","volume":"59","author":"White","year":"2014","journal-title":"Mol. Cell Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"103453","DOI":"10.1016\/j.critrevonc.2021.103453","article-title":"Rethinking Mechanisms of Neurotoxicity with BCMA Directed Therapy","volume":"166","author":"Mohyuddin","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"879608","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune Effector Cell Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor-T Cell Therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological Updates: Neurological Complications of CAR-T Therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J. Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and Hypokinetic Movement Disorder with Features of Parkinsonism Following BCMA-Targeting CAR-T Cell Therapy","volume":"27","author":"Aleman","year":"2021","journal-title":"Nat. Med."},{"key":"ref_61","unstructured":"FDA (2021). Cber Package Insert\u2014ABECMA, FDA."},{"key":"ref_62","unstructured":"(2023, April 10). Bristol Myers Squibb\u2014Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and Bluebird Bio\u2019s Abecma (Idecabtagene Vicleucel) in Relapsed or Refractory Multiple Myeloma. Available online: https:\/\/news.bms.com\/news\/details\/2021\/Long-Term-Data-from-Pivotal-KarMMa-Study-Continue-to-Demonstrate-Deep-and-Durable-Responses-and-Predictable-Safety-Profile-with-Bristol-Myers-Squibb-and-bluebird-bios-Abecma-idecabtagene-vicleucel-in-Relapsed-or-Refractory-Multiple-Myeloma\/default.aspx."},{"key":"ref_63","unstructured":"FDA (2022). Cber Package Insert\u2014CARVYKTI, FDA."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.HS9.0000829604.35383.e8","article-title":"P08: Cartitude-2 Update: Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen\u2013Directed Chimeric Antigen Receptor T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy","volume":"6","author":"Einsele","year":"2022","journal-title":"Hemasphere"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 Study of CART-DdBCMA for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv."},{"key":"ref_66","unstructured":"FDA (2022). Cder Package Insert\u2014Teclistamab, FDA."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow. Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of Infections with B-Cell Maturation Antigen-Directed Immunotherapy in Multiple Myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T Cells: A Report on Current Challenges and Future Directions from the EPICOVIDEHA Survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early Cytopenias and Infections after Standard of Care Idecabtagene Vicleucel in Relapsed or Refractory Multiple Myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e2238961","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of Humoral Immunodeficiency with Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Mazahreh, F., Mazahreh, L., Schinke, C., Thanendrarajan, S., Zangari, M., Shaughnessy, J.D., Zhan, F., Van Rhee, F., and Al Hadidi, S.A. (2023). Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis. Blood Adv.","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2022.40.16_suppl.8032","article-title":"A Novel, Immunotherapy-Based Approach for the Treatment of Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Phase 1b Results for Daratumumab in Combination with Teclistamab (a BCMA \u00d7 CD3 Bispecific Antibody)","volume":"40","author":"Reece","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Searle, E. (2022, January 10\u201313). Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study. Proceedings of the ASH Annual Meeting & Exposition, Virtual.","DOI":"10.1182\/blood-2022-159711"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2021-148813","article-title":"Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Chari","year":"2021","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2022-162738","article-title":"Elranatamab in Combination with Daratumumab for Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort","volume":"140","author":"Grosicki","year":"2022","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and Safety of Elranatamab in Patients with Relapsed\/Refractory Multiple Myeloma Na\u00efve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood-2022-166494","article-title":"Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma","volume":"140","author":"Raje","year":"2022","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"10140","DOI":"10.1182\/blood-2022-159969","article-title":"Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed\/Refractory Multiple Myeloma: A Phase 1\/2 First-in-Human Study","volume":"140","author":"Bumma","year":"2022","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2022-167008","article-title":"A Phase 1 First-in-Human Study of Abbv-383, a BCMA \u00d7 CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Voorhees","year":"2022","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Early Experience from a Phase I Study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC.; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) \u00d7 CD3 T-Cell Engager (TCE), in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae(bispecific T-cell engager) Molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.22.02197","article-title":"Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma","volume":"41","author":"Cliff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"40","author":"Shah","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2022-159381","article-title":"Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"key":"ref_89","unstructured":"Costa, L.J., Wong, S.W., Berm\u00fadez, A., de la Rubia, J., Mateos, M.-V., Ocio, E.M., Rodr\u00edguez-Otero, P., San-Miguel, J., Li, S., and Sarmiento, R. (2021). Early-Phase Trial Suggests Bispecific Antibody CC-93269 Has Activity in Relapsed\/Refractory Multiple Myeloma. ASH Clin. News."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral Infection\/Reactivation during Long-Term Follow-up in Multiple Myeloma Patients with Anti-BCMA CAR Therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2019000888","article-title":"Safety of CAR T-Cell Therapy in Patients with B-Cell Lymphoma and Chronic Hepatitis B or C Virus Infection","volume":"133","author":"Strati","year":"2019","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","article-title":"Management of Viral Hepatitis in Patients with Haematological Malignancy and in Patients Undergoing Haemopoietic Stem Cell Transplantation: Recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)","volume":"16","author":"Mallet","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zignego, A.L., Giannini, C., Gragnani, L., Piluso, A., and Fognani, E. (2012). Hepatitis C Virus Infection in the Immunocompromised Host: A Complex Scenario with Variable Clinical Impact. J. Transl. Med., 10.","DOI":"10.1186\/1479-5876-10-158"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/cncr.32411","article-title":"Successful Anti-CD19 CAR T-Cell Therapy in HIV-Infected Patients with Refractory High-Grade B-Cell Lymphoma","volume":"125","author":"Abramson","year":"2019","journal-title":"Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene Ciloleucel CD19 CAR-T Cell Therapy Results in High Rates of Systemic and Neurologic Remissions in Ten Patients with Refractory Large B Cell Lymphoma Including Two with HIV and Viral Hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I Prevent Infections in Patients Receiving CD19-Targeted Chimeric Antigen Receptor T Cells for B-Cell Malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: A Comprehensive Review of Current Data and Implications for Clinical Practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for Screening, Monitoring, Prevention, and Prophylaxis of Infections in Adult and Pediatric Patients Receiving CAR T-Cell Therapy: A Position Paper","volume":"49","author":"Iacoboni","year":"2021","journal-title":"Infection"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus Guidelines and Recommendations for Infection Prevention in Multiple Myeloma: A Report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged Hematologic Toxicity Following Treatment with Chimeric Antigen Receptor T Cells in Patients with Hematologic Malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Gill, S., and Brudno, J.N. (2021). CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. Am. Soc. Clin. Oncol. Educ. Book, e246\u2013e265.","DOI":"10.1200\/EDBK_320085"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Luo, W., Li, C., Zhang, Y., Du, M., Kou, H., Lu, C., Mei, H., and Hu, Y. (2022). Adverse Effects in Hematologic Malignancies Treated with Chimeric Antigen Receptor (CAR) T Cell Therapy: A Systematic Review and Meta-Analysis. BMC Cancer, 22.","DOI":"10.1186\/s12885-021-09102-x"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2022-165646","article-title":"Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed\/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy","volume":"140","author":"Thibaud","year":"2022","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1182\/blood-2022-165266","article-title":"The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Rejeski","year":"2022","journal-title":"Blood"},{"key":"ref_107","unstructured":"(2023, April 11). KarMMa Trial ORR|ABECMA\u00ae (Idecabtagene Vicleucel). Available online: https:\/\/www.abecmahcp.com\/efficacy."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41409-022-01664-z","article-title":"Safety and Feasibility of Outpatient Chimeric Antigen Receptor (CAR) T-Cell Therapy: Experience from a Tertiary Care Center","volume":"57","author":"Borogovac","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine Is Safe and Effective for Lymphodepletion before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas","volume":"33","author":"Ghilardi","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_111","first-page":"5073","article-title":"Cytopenia after Chimeric Antigen Receptor T Cell Immunotherapy in Relapsed or Refractory Lymphoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00277-022-04889-6","article-title":"Thrombopoietin Receptor Agonist for Treating Bone Marrow Aplasia Following Anti-CD19 CAR-T Cells-Single-Center Experience","volume":"101","author":"Perry","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"12764","DOI":"10.1182\/blood-2022-164729","article-title":"Early Cytopenias and Infections Following Chimeric Antigen Receptor T-Cell Therapy: A Single Center Experience","volume":"140","author":"McGann","year":"2022","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage Activation Syndrome-like (MAS-L) Manifestations Following BCMA-Directed CAR T Cells in Multiple Myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jdcr.2022.11.013","article-title":"Onychomadesis and Palmoplantar Keratoderma Associated with Talquetamab Therapy for Relapsed and Refractory Multiple Myeloma","volume":"31","author":"Narayan","year":"2023","journal-title":"JAAD Case Rep."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/7\/467\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:04:35Z","timestamp":1760126675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/7\/467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":115,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["curroncol30070467"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30070467","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}